Literature DB >> 22698939

Improvement of drug safety by the use of lipid-based nanocarriers.

Sok Bee Lim1, Amrita Banerjee, Hayat Önyüksel.   

Abstract

Drug toxicity is an important factor that contributes significantly to adverse drug events in current healthcare practice. Application of lipid-based nanocarriers in drug formulation is one approach to improve drug safety. Lipid-based delivery systems include micelles, liposomes, solid lipid nanoparticles, nanoemulsions and nanosuspensions. These carriers are generally composed of physiological lipids well tolerated by human body. Delivery of water-insoluble drugs in these formulations increases their solubility and stability in aqueous media and eliminates the need for toxic co-solvents or pH adjustment to solubilize hydrophobic drugs. Association or encapsulation of peptides/proteins within lipid-based carriers protects the labile biologics against enzymatic degradation, hence reducing the therapeutic dose required and risk of dose-dependent toxicity. Most importantly, lipid-based nanocarriers alter the pharmacokinetics and biodistribution of drugs through passive and active targeting, leading to increased drug accumulation at target sites while significantly decreasing non-specific distribution to other tissues. Furthermore, surface modification of these nanocarriers reduces immunogenicity of drug-carrier complexes, imparts stealth by preventing opsonization and removal by phagocytes and minimizes interaction with circulating blood components. In view of heightening attention on drug safety in patient treatment, lipid-based nanocarrier is therefore an important and promising option for formulation of pharmaceutical products to improve treatment safety and efficacy.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22698939     DOI: 10.1016/j.jconrel.2012.06.002

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  50 in total

1.  Ocular disposition of ciprofloxacin from topical, PEGylated nanostructured lipid carriers: Effect of molecular weight and density of poly (ethylene) glycol.

Authors:  Sai Prachetan Balguri; Goutham R Adelli; Karthik Yadav Janga; Prakash Bhagav; Soumyajit Majumdar
Journal:  Int J Pharm       Date:  2017-06-17       Impact factor: 5.875

Review 2.  Emerging targets and novel approaches to Ebola virus prophylaxis and treatment.

Authors:  Jin Huk Choi; Maria A Croyle
Journal:  BioDrugs       Date:  2013-12       Impact factor: 5.807

3.  Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications.

Authors:  Xiomara Calderón-Colón; Giorgio Raimondi; Jason J Benkoski; Julia B Patrone
Journal:  J Vis Exp       Date:  2015-11-17       Impact factor: 1.355

4.  Fluorescence-quenching of a liposomal-encapsulated near-infrared fluorophore as a tool for in vivo optical imaging.

Authors:  Felista L Tansi; Ronny Rüger; Markus Rabenhold; Frank Steiniger; Alfred Fahr; Ingrid Hilger
Journal:  J Vis Exp       Date:  2015-01-05       Impact factor: 1.355

Review 5.  Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals.

Authors:  Shu Wang; Rui Su; Shufang Nie; Ming Sun; Jia Zhang; Dayong Wu; Naima Moustaid-Moussa
Journal:  J Nutr Biochem       Date:  2013-11-05       Impact factor: 6.048

6.  The shape/morphology balance: a study of stealth liposomes via fractal analysis and drug encapsulation.

Authors:  Natassa Pippa; Faidra Psarommati; Stergios Pispas; Costas Demetzos
Journal:  Pharm Res       Date:  2013-06-07       Impact factor: 4.200

Review 7.  Anticancer activities of phytoconstituents and their liposomal targeting strategies against tumor cells and the microenvironment.

Authors:  Jing Zhang; Xiang Li; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2020-05-28       Impact factor: 15.470

8.  Solubilization of therapeutic agents in micellar nanomedicines.

Authors:  Lela Vuković; Antonett Madriaga; Antonina Kuzmis; Amrita Banerjee; Alan Tang; Kevin Tao; Neil Shah; Petr Král; Hayat Onyuksel
Journal:  Langmuir       Date:  2013-12-09       Impact factor: 3.882

9.  VIP-targeted Cytotoxic Nanomedicine for Breast Cancer.

Authors:  Aparna Dagar; Antonina Kuzmis; Israel Rubinstein; Marin Sekosan; Hayat Onyuksel
Journal:  Drug Deliv Transl Res       Date:  2012-12-01       Impact factor: 4.617

10.  Immunostimulatory lipid nanoparticles from herbal medicine.

Authors:  Tal H Hasson; Anna Takaoka; Roberto de la Rica; Hiroshi Matsui; Gabriela Smeureanu; Charles M Drain; Akira Kawamura
Journal:  Chem Biol Drug Des       Date:  2014-02-05       Impact factor: 2.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.